Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses.

Factor V Leiden (FVL) is associated with venous thrombosis; however, an association between FVL and arterial thrombosis remains controversial. We investigated FVL as a risk factor for myocardial infarction (MI), ischemic stroke (IS), or non-MI ischemic heart disease (non-MI-IHD). The design was 3 case-control studies and 3 prospective studies with 21 years' follow-up. The setting was the general population in Copenhagen, Denmark. The participants for The Copenhagen City Heart Study were 20- to 95-year-old participants without cardiovascular disease (control population, n = 7907) or participants diagnosed with MI (n = 469), IS (n = 231), or non-MI-IHD (n = 365). In addition, 3 independent patient populations from Copenhagen University Hospital with MI (n = 493), IS (n = 231), or non-MI-IHD (n = 448) were included. We measured FVL genotype; major cardiovascular risk factors; and MI, IS, and non-MI-IHD incidence and prevalence. Prevalences of FVL heterozygotes and homozygotes in control subjects from the general population were 7.7% and 0.2%. Odds ratios and relative risks of MI in FVL carriers (heterozygotes + homozygotes) versus noncarriers were 1.24 (95% confidence interval [CI], 0.91-1.69) and 0.83 (0.58-1.20) in case-control and prospective studies, respectively. Corresponding risks for IS were 0.92 (95% CI, 0.56-1.53) and 0.68 (0.45-1.04), and for non-MI-IHD 1.01 (95% CI, 0.71-1.44) and 0.97 (0.66-1.42). Findings from The Copenhagen City Heart Study suggest that FVL is not associated with MI, IS, or non-MI-IHD.

[1]  H. Mannebach,et al.  Evidence against heterozygous coagulation factor V 1691 G→A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction , 1995, Journal of Molecular Medicine.

[2]  J. Vacek,et al.  Incidence of Factor V Leiden in Patients with Acute Myocardial Infarction , 2004, Journal of Thrombosis and Thrombolysis.

[3]  G. Hankey,et al.  Inherited Thrombophilia in Ischemic Stroke and Its Pathogenic Subtypes , 2001, Stroke.

[4]  A. Wu,et al.  Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. , 2001, The American journal of cardiology.

[5]  E. Yilmaz,et al.  Plasminogen Activator Inhibitor-1 4G/5G Polymorphism in Turkish Children With Cerebral Infarct and Effect on Factor V 1691 A Mutation , 2001, Journal of child neurology.

[6]  A. LaCroix,et al.  Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. , 2001, JAMA.

[7]  Ş. Kaplan,et al.  Factor V Leiden and its relation to left ventricular thrombus in acute myocardial infarction , 2001, Acta cardiologica.

[8]  P. Schnohr.  The Copenhagen City Heart Study : Østerbroundersøgelsen : tables with data from the third examination 1991-1994 , 2001 .

[9]  R. Junker,et al.  Symptomatic Ischemic Stroke in Full-Term Neonates: Role of Acquired and Genetic Prothrombotic Risk Factors , 2000, Stroke.

[10]  G. Rechavi,et al.  Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. , 2000, Stroke.

[11]  B. Damasceno,et al.  Inherited Thrombophilia as a Risk Factor for the Development of Ischemic Stroke in Young Adults , 2000, Thrombosis and Haemostasis.

[12]  J. Blanc,et al.  Prevalence of Factor V Leiden in Patients with Myocardial Infarction and Normal Coronary Angiography , 1999, Thrombosis and Haemostasis.

[13]  F. Triposkiadis,et al.  Resistance to activated protein C and FV leiden mutation in patients with a history of acute myocardial infarction or primary hypertension. , 2000, American journal of hypertension.

[14]  W. Kreuz,et al.  Prothrombotic risk factors in childhood stroke and venous thrombosis , 1999, European Journal of Pediatrics.

[15]  I. Moreira,et al.  Genetic Risk Factors in Acute Coronary Disease , 1999, Pathophysiology of Haemostasis and Thrombosis.

[16]  G J Tsongalis,et al.  Polymorphisms in the genes for coagulation factors II, V, and VII in patients with ischemic heart disease. , 1999, Archives of pathology & laboratory medicine.

[17]  A. von Eckardstein,et al.  Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. , 1999, Blood.

[18]  M. Margaglione,et al.  Prothrombotic genetic risk factors in young survivors of myocardial infarction. , 1999, Blood.

[19]  M. Margaglione,et al.  Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[20]  E. Chalmers,et al.  Factor V Leiden, Prothrombin 20210 G → A and the MTHFR C677T Mutations in Childhood Stroke , 1999, Thrombosis and Haemostasis.

[21]  B. Lämmle,et al.  Coagulation factors II, V, VII, and X, prothrombin gene 20210G-->A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[22]  B. Modan,et al.  Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. , 1999, Blood.

[23]  Factor V Arg506Gln mutation is not associated with cardiovascular mortality in older women. , 1999, American journal of epidemiology.

[24]  P. Ridker,et al.  Factor V Leiden is not a risk factor for myocardial infarction among young women. , 1999, Blood.

[25]  A. Gardemann,et al.  The Factor II G20210A and Factor V G1691A Gene Transitions and Coronary Heart Disease , 1999, Thrombosis and Haemostasis.

[26]  J. Godin,et al.  Do inherited prothrombotic factors have a role in myocardial infarction with normal coronary arteriogram? , 1998, Journal of internal medicine.

[27]  G. Assmann,et al.  Plasminogen activator inhibitor-1 4G/5G-polymorphism and factor V Q506 mutation are not associated with myocardial infarction in young men. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[28]  F. Kirkham,et al.  Inherited prothrombotic states and ischaemic stroke in childhood , 1998, Journal of neurology, neurosurgery, and psychiatry.

[29]  C. Kessler,et al.  Prevalence of factor V Leiden mutation in young adults with cerebral ischaemia: a case-control study on 225 patients , 1998, Journal of Neurology.

[30]  J. Eichner,et al.  Role of factor V Leiden mutation in patients with angiographically demonstrated coronary artery disease. , 1998, Thrombosis research.

[31]  V. Khavinson,et al.  Age as a risk factor for myocardial infarction in Leiden mutation carriers. , 1998, Molecular genetics and metabolism.

[32]  P. Chiusolo,et al.  Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. , 1998, Blood.

[33]  L. Kuller,et al.  Factor V Leiden Is not a Risk Factor for Arterial Vascular Disease in the Elderly: Results from the Cardiovascular Health Study , 1998, Thrombosis and Haemostasis.

[34]  F R Rosendaal,et al.  Risk of Myocardial Infarction Associated With Factor V Leiden or Prothrombin Interaction of Coagulation Defects and Cardiovascular Risk Factors : Increased , 1998 .

[35]  G. B. Petersen,et al.  The Arg506Gln mutation (FV Leiden) among a cohort of 4188 unselected Danish newborns. , 1998, Thrombosis research.

[36]  G. Evans,et al.  No association between factor V Leiden mutation and coronary heart disease or carotid intima media thickness: the NHLBI Family Heart Study. , 1998, Thrombosis research.

[37]  T. Raghunathan,et al.  Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A) , 1998, Stroke.

[38]  J. Corral,et al.  Factor-V (Arg506 --> Gln) mutation in ischemic cerebrovascular disease. , 1997, Haemostasis.

[39]  T. Raghunathan,et al.  Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. , 1997, Blood.

[40]  M. Prins,et al.  The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). , 1997, The New England journal of medicine.

[41]  E. Leatham,et al.  Factor V Leiden polymorphism (FV Q506) in patients with ischaemic heart disease, and in different populations groups. , 1996, Journal of human hypertension.

[42]  D. Ardissino,et al.  Factor V (Arg506⟶ Gln) Mutation in Young Survivors of Myocardial Infarction , 1996, Thrombosis and Haemostasis.

[43]  B. Dahlbäck,et al.  Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries , 1996, Journal of internal medicine.

[44]  R. Press,et al.  Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. , 1996, Stroke.

[45]  J. Emmerich,et al.  Mutation in the factory V gene and the risk of myocardial infarction. , 1995 .

[46]  J. Barrett,et al.  Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[47]  P. Ridker,et al.  Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. , 1995, The New England journal of medicine.

[48]  M. Kaste,et al.  Arg506GIn Factor V Mutation (Factor V Leiden) in Patients with Ischaemic Cerebrovascular Disease and Survivors of Myocardial Infarction , 1995, Thrombosis and Haemostasis.

[49]  R. Baker,et al.  Premature ischaemic heart disease and the gene for coagulation factor V , 1995, Nature Medicine.

[50]  B. Winkelmann,et al.  Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease , 1995, The Lancet.

[51]  D. Valla,et al.  Budd-Chiari syndrome and factor V Leiden mutation , 1995, The Lancet.

[52]  A. Evans,et al.  Myocardial infarction, Arg 506 to Gin factor V mutation, and activated protein C resistance , 1995, The Lancet.

[53]  D. Sackett,et al.  Cochrane Collaboration , 1994, BMJ.

[54]  J. Voorberg,et al.  Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V , 1994, The Lancet.

[55]  B. Evatt,et al.  Activated protein C resistance caused by Arg506Gln mutation in factor Va , 1994, The Lancet.

[56]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[57]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Bruce Bullock,et al.  Risk of What , 1986 .